# Pembrolizumab

## KEYTRUDA inj 100mg/4mL

| TAH Drug Code      | [**IKEY1**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IKEY1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | [Melanoma] 2 mg/kg infused over 30 minutes once every 3 weeks until disease progression or unacceptable toxicity. [Non-Small Cell Lung Cancer (NSCLC)] 200 mg for untreated patients or 2 mg/kg as a single agent for previously treated patients infused over 30 minutes once every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months. [Classical Hodgkin Lymphoma (cHL), Head and Neck Squamous Cell Cancer (HNSCC), Urothelial Carcinoma] 200 mg infused over 30 minutes once every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Hypersensitivity to pembrolizumab or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | >10%: Cardiovascular: Facial edema (10%) Central nervous system: Fatigue (43%) Dermatologic: Pruritus (28%), skin rash (24%; immune-mediated: 1%) Endocrine & metabolic: Hyperglycemia (49%), hypoalbuminemia (37%), hyponatremia (37%), hypertriglyceridemia (33%), decreased serum bicarbonate (22%), hypocalcemia (21%) Gastrointestinal: Constipation (22%), nausea (22%), decreased appetite (20%), diarrhea (20%), abdominal pain (13%), vomiting (13%) Hematologic & oncologic: Anemia (44%; grades 3/4: 10%), lymphocytopenia (40%; grades 3/4: 9%) Hepatic: Increased serum alkaline phosphatase (26%), increased serum AST (24%), increased serum ALT (21%) Neuromuscular & skeletal: Arthralgia (14%) Respiratory: Dyspnea (?20%), cough (18%) Miscellaneous: Fever (14%) 1% to 10%: Central nervous system: Confusion (>2%), peripheral neuropathy (2%) Endocrine & metabolic: Hypothyroidism (immune-mediated; 9%), hyperthyroidism (immune-mediated; 3%) Gastrointestinal: Colitis (immune-mediated; 2%) Immunologic: Antibody development (2%) Neuromuscular & skeletal: Weakness (10%), arthritis (immune-mediated; 2%) Respiratory: Pneumonitis (3%), pleural effusion (>2%), pneumonia (>2%), respiratory failure (>2%) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data – Potential Toxicity(Mother)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

